Loss narrows year-over-year. Apyx Medical Corporation (NASDAQ: APYX) reported an adjusted loss of $0.06 per share for Q4 2025, narrowing 50% from the $0.12 per share loss in Q4 2024. The medical device maker’s GAAP loss came in at $0.03 per share, with the net loss totaling $1.3 million. No consensus estimate was available for comparison.
Revenue surges 34.8%. Q4 2025 revenue reached $19.2 million, up 34.8% from $14.2 million in the year-ago quarter. The company generated gross profit of $12.0 million against cost of revenue of $7.2 million, while adjusted EBITDA turned positive at $700,000. Management issued fiscal 2026 revenue guidance of $57.5 million to $58.5 million. Shares traded at $3.12 on volume of 188,565, with the stock flat on the day.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share first appeared on Alphastreet.
